1. Annual Report 2025
  2. Research
  3. ISAC

ISAC

Interventions in Health and Community Activities

Multidisciplinary transversal group integrated by 20 professionals (6 doctors and 5 doctoral students) of different profiles who develop their research in Primary Care, frequently collaborating with other groups and entities. Its lines of research are related to lifestyle interventions, preventive health promotion activities (nutrition, smoking, physical activity, vaccines), and patient quality and safety, with a focus on communities, using information and communication technologies (ICTs). Different members of the group have led projects funded in competitive calls (FIS, PERIS, IDIAPJGol, etc.) and have obtained funding from contracts and agreements with European entities. The group takes into account the gender perspective, citizen participation, dissemination and socialization of science. Regarding scientific dissemination, priority will be given to the publication "OpenAcces" and in the digital repository SCIENTIA of the Department of Health.

Group projects

  • Self-controlled case series (SCCS) study of COVID-19 vaccines and myocarditis and pericarditis (GVDN-VAC4EU-Myocarditis). 2022-2025. IP: Felipe Villalobos Martínez.

  • Salud pública y Medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la Cohorte IMPaCT (Obes-IMPaCT). (PMP22/00003). Instituto de Salud Carlos III. 2025-2026. IP: Josep Basora Gallisà.

  • Regional Research Protocol to evaluate the effectiveness of dengue vaccines and the risk of Vaccine-Associated Enhanced Disease (VAED) in the Americas. American Health Organization/World Health Organization (PAHO/OPS). 2025-2027. IP: Felipe Villalobos Martínez.

  • Proyecto INSIGNIA. Una iniciativa para mejorar el seguimiento de los pacientes con Enfermedad Pulmonar Obstructiva Crónica. AstraZeneca Farmacéutica Spain, S.A. 2022-2025. IP: Francisco Martín Luján.

  • Projecte INSIGNIA 2: Implementació d'una estratègia per millorar la detecció de la malaltia pulmonar obstructiva crònica en pacients amb un ingrés hospitalari recent per malaltia cardiovascular. Fundació d'Atenció Primària (FAP) - CAMFIC. 2025-2028. IP: Antoni Santigosa Ayala.

  • Post-Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID -19) Vaccine. (C4591021). Fondazione Penta ETS. 2021-2025. IP: Felipe Villalobos Martínez.

  • Evaluación del efecto del consumo de tabaco en indicadores de salud del recien nacido hasta los 24 meses. 2025-2028. IP: Cristina Rey Reñones.

  • Evaluación de SINERGIAPS, una intervención dirigida a mejorar la seguridad del paciente en centros de salud en España en base a las percepciones y experiencias de los propios pacientes. 2023-2026. IP: Montserrat Gens Barberà.

  • Evaluación de le eficacia de 2 intervenciones de Audit&Feedback para reducir la prescripción potencialmente Inapropiada de Medicación y la prescripción de antibióticos en atención primaria. Estudio AIMab: Ensayo clínico multicéntrico. (PI22/01669). Instituto de Salud Carlos III. 2024-2026. IP: Ferran Bejarano Romero.

  • Evaluación de la seguridad del paciente en atención primaria en España en base a las percepciones y experiencias de los propios pacientes: Estudio SINERGIAPS 2. (PI22/01822). Instituto de Salud Carlos III. 2022-2026. IP: Montserrat Gens Barberà.

  • Eficàcia d'una formació online en maniobres de Ressuscitació cardiopulmonar i l'ús del Desfibril·lador Extern Automatitzat (DEA) a través d'una plataforma virtual. 2023-2026. IP: Cristina Rey Reñones.

  • Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen. UMC Utrecht (University Medical Center Utrecht). 2022-2025. IP: Felipe Villalobos Martínez.

  • Efectivitat d'una intervenció formativa basada en l'ús de la luminiscència sobre la higiene de mans en població general_ projecte hima. ICS - Institut Català de la Salut. 2025-2026. IP: Josep Basora Gallisà.

  • Efectivitat d'una Intervenció Educativa sobre la Higiene de Mans en Alumnat d'Escoles Sentinella. 2023-2026. IP: Josep Basora Gallisà.

  • Efectividad de una formación online en maniobras de reanimación cardiopulmonar a una red de voluntarios para aumentar la supervivencia en parada cardiopulmonar. Estudio EFORCP. (PI23/00288). Instituto de Salud Carlos III. 2024-2026. IP: Ester Granado Font.

  • Efectividad de una aplicación para dispositivos móviles en la deshabituación de tabaco en mujeres embarazadas (TOBBGEST): ensayo comunitario aleatorio. (PI21/01058). Instituto de Salud Carlos III. 2021-2026. IP: Cristina Rey Reñones.

  • Efecte de la Dieta Mediterrània sobre la funció pulmonar en fumadors sense patologia respiratòria prèvia: l'assaig clínic MEDIS-TAR (Mediterranean Diet and Smoking in Tarragona). Col·legi Oficial de Metges de Tarragona. 2023-2026. IP: Francisco Martín Luján.

  • Disseny i avaluació d'una plataforma interactiva d'activitats comunitàries promogudes des de l'atenció primària per a fomentar la salut i el benestar en una població d'una àrea bàsica de salut. (SLT021/21/000073). Generalitat Catalunya. 2022-2025. IP: Maria Roser Pedret Llaberia.

  • Consum i experiència amb el tabac durant l'embaràs. Estudi qualitatiu. 2023-2026. IP: Cristina Rey Reñones.

  • Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (WP1). European Medicines Agency (EMA). 2021-2025. IP: Felipe Villalobos Martínez.

  • Clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273 (ELASOMERAN). Julius Clinical Research B.V. 2023-2025. IP: Felipe Villalobos Martínez.

  • Barreres, facilitadors i acceptabilitat de l'equip docent sobre la intervenció d'higiene de mans en alumnat d'Escoles Sentinella. Estudi qualitatiu. 2025-2025. IP: Josep Basora Gallisà.

  • Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe. (C4591052). 2024-2027. IP: Felipe Villalobos Martínez.

  • Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID 19) Vaccine. (C4591038). Fondazione Penta ETS. 2022-2025. IP: Felipe Villalobos Martínez.

  • A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK. (C3671038). European Medicines Agency (EMA); Pfizer, S.A. 2025-2025. IP: Felipe Villalobos Martínez.

  • A Post-Authorisation Safety Study of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK. (C3671026). Pfizer Ltd; Pfizer, S.A. 2025-2028. IP: Felipe Villalobos Martínez.

  • A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU: Study protocol for the occurrence of flares of Graves´ disease, Hashimoto´s thyroiditis, polyarteritis nodosa, autoimmune hepatitis, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, erythema nodosum, systemic lupus erythematosus, and ulcerative colitis using electronic healthcare data sources. European Medicines Agency (EMA). 2024-2027. IP: Felipe Villalobos Martínez.

  • A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU. Universiteit Utrecht. 2024-2027. IP: Felipe Villalobos Martínez.

  • Utilidad y Rendimiento de la Detección de Alteraciones Espirométricas, Mediante una Aplicación Móvil, en Fumadores Asintomáticos. ICS - Institut Català de la Salut. 2022-2026. IP: Darinka Savic Pesic.

  • Intervencions sanitàries i activitats comunitàries: línia de recerca en tabaquisme. (INTENS-23/3). ICS - Institut Català de la Salut. 2024-2026. IP: Antoni Santigosa Ayala.

  • Intensificació ISCIII Cristina Rey. (INT23/00021). Instituto de Salud Carlos III. 2023IP: Cristina Rey Reñones.

  • Grup TICS-AP: Tecnologies de la informació i Comunicació en Atenció Primària. ICS - Institut Català de la Salut. 2023IP: Ester Granado Font.

  • Effectiveness of a motivational intervention based on spirometry results to achieve smoking cessation in primary healthcare patients: randomised, parallel, controlled multicentre study. Col·legi Oficial de Metges de Tarrahgona. IP: Francisco Martín Luján.

  • Efectivitat d'una App per a la deshabituació del tabac en gestants. (PREDOC_ECO-24/10). ICS - Institut Català de la Salut. 2025-2030. IP: Maria Agràs Guàrdia.

  • Efectivitat d'una App per a la deshabituació del tabac en gestants (TOBBGEST). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). IP: Maria Agràs Guàrdia.

  • Efectividad de una formación online en maniobras de reanimación cardiopulmonar a una red de voluntarios para aumentar la supervivencia en parada cardiopulmonar. Estudio EFORCP. (INT24/00056). Instituto de Salud Carlos III. 2025-2026. IP: Ester Granado Font.

  • Biomarcadors predictius de la gravetat de la COVID-19 en pacients infectats per SARS-CoV-2 amb obesitat i/o síndrome metabòlica. ICS - Institut Català de la Salut. 2023-2027. IP: Carles Perpiñan Auguet.

  • App per a la teràpia dedeshabituació tabaquica.TOBBSTOP. Viladecans Style Oulet - VTSO. IP: Cristina Rey Reñones.

Grou Publications

  • Luján FM, Alberich RS. The usefulness of studying visceral fat for early stratification of atherogenic risk: from conventional anthropometry to more accurate measurements. Clin. Invest. Arterioscler. 2025;37(6):500874-500874. PMID:41276337.

  • Fortuny DB, López SR, Martínez Torres S, Rey Reñones C, Martín Luján FM. The Influence of Virtual Reality Glasses Use on the Quality of Life of Older Adults: Protocol for a Prospective, Longitudinal Quasi-Experimental Study. JMIR RES. Protoc. 2025;14PMID:41432992.

  • Zabaleta Olmo E, Rey Renones C, Marchal Torralbo A, Sauch Valmana G, Calvet Tort G, Planas Campmany C et al. Structural Validity and Reliability of an Adapted Practice Environment Scale-Nursing Work Index for Primary Health Care Nurses. Res. Nurs. Health. 2025;48(5):533-544. PMID:40464625.

  • Pedret Llaberia R, Basora Gallisà T, Martínez Torres S, Rodríguez Soler S, Pallejà Millán M, Buscemi A et al. Social and Demographic Determinants of Health: A Descriptive Study on the Impact of Place of Residence and Community Belonging. Healthcare. 2025;13(10):PMID:40427962.

  • Nasreen S, Jiang Y, Lu H, Lee A, Cutland CL, Gentile A et al. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study. Vaccine. 2025;60127291-127291. PMID:40440921.

  • Zabaleta Olmo E, Reñé A, Sauch Valmaña G, Rios Jiménez A, Marchal Torralbo A, Rey Reñones C et al. Practice Environment Scale-Nursing Work Index for use in primary health care: a qualitative content validity study. RqR Enferm. Comunitaria. 2025;13(3).

  • Castillo Cano B, Riefolo F, Villalobos F, Martín Pérez M, Messina D, Elbers R et al. Impact and Effectiveness of COVID-19 mRNA Vaccination Against COVID-19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain. Pharmacoepidemiol. Drug Saf. 2025;34(11): PMID:41125425.

  • Clua Espuny JL, Hernández Pinilla A, Gentille Lorente D, Muria Subirats E, Forcadell Arenas T, de Diego Cabanes C et al. Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study). Biomedicines. 2025;13(1): PMID:39857703.

  • Fiol deRoque MA, Valderas JM, Serrano Ripoll MJ, Gens Barbarà M, Martín Luján F, Sánchez Freire E et al. Evaluating SinergiAPS, an intervention based on patient feedback to improve patient safety in primary care: a cluster randomized trial. BMC Med. 2025;23(1):202-202. PMID:40189506.

  • Azeli Y, Barbería E, Solà Muñoz S, Landín I, Fernández A, Rey Reñones C et al. Epidemiology of sudden cardiac arrest in the western Mediterranean area based on a prospective registry. BMJ Glob. Health. 2025;10(11): PMID:41213660.

  • Kou XR, Millán MP, Canals J, Moreno VR, Renzetti S, Arija V. Effects of prenatal exposure to multiple heavy metals on infant neurodevelopment: A multi-statistical approach?. Environ. Pollut. 2025;367125647-125647. PMID:39761717.

  • Romero FB, Molés VA, Porrúa DM, Guerrero EL, Barriga HS, Vilarrasa LC. Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes. Aten. Prim. 2025;57(11):103354-103354. PMID:40925137.

  • Hernández Martínez C, Canals Sans J, Patricio D, Sombrero I, Ruiz F, Rey Reñones C. Effectiveness of an online biopsychosocial cognitive-behavioural preventive intervention to improve wellbeing and mental health during pregnancy. Randomized controlled trial (BienGestar). BMC Pregnancy Childbirth. 2025;26(1): PMID:41390643.

  • Hernández Vidal N, Pujol Vidal M, Mengíbar García Y, Ayala Villuendas D, Contel Segura JC, Martínez Torres S et al. Design, Implementation, and Evaluation of Healthcare Visual Map Tool for Health Workers to Improve Quality of Life of Home Care Patients: Study Protocol. Healthcare. 2025;13(6): PMID:40150476.

  • Maisonneuve E, Luxi N, Bellitto C, Ciccimarra F, Raethke M, van Hunsel F et al. Cohort event monitoring of booster COVID-19 vaccine safety using patient-reported outcomes in pregnant women. Front Drug Saf Regul. 2025;51689349-1689349. PMID:41532034.

  • Zwiers LC, Grobbee DE, Schneijdenberg R, Baljé C, Laurent STS, Esposito DB et al. Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources. Vaccines. 2025;13(7):PMID:40733732.

  • Seguí DR, Forcadell MJ, Vila Córcoles A, De Diego Cabanes C, Ochoa Gondar O, Lujan FM et al. Classification rule for ten year MACE Risk in primary care tarragona older adults with type2 diabetes: a CHAID decision-tree analysis. BMC Prim. Care. 2025;26(1):129-129. PMID:40281435.

  • Motevalizadeh E, Díaz López A, Jardí C, Rey Reñones C, Martín Luján F, Arija V. Cardiometabolic Markers Associated With Altered Fetal Growth in Mediterranean Cohort. Matern. Child Nutr. 2025;21(4): PMID:40767273.

  • Minana Castellanos M, Fernández Martín MI, Rodríguez Barragán M, Marques M, Sisó A, Basora J et al. Burnout among Catalan general practitioners. A repeated cross-sectional study, during and after the COVID-19 pandemic. Eur. J. Gen. Pract. 2025;31(1):2485073-2485073. PMID:40208687.

  • Soler A, Huguet A, Leiva A, Vicens C, Bejarano Romero F, Sempere E et al. A pharmacist-led educational and audit & feedback strategy to reduce antibiotic prescription in primary care: the AFA study. BMC Prim. Care. 2025;26(1): PMID:40684119.

  • Zwiers L, van der Velden F, St Laurent S, Esposito DB, Zhu L, Urdaneta V et al. Risk Factors for Myocarditis/Pericarditis following Mrna-1273 Vaccination: Interim Analysis of a VAC4EU Case-Cohort Study. Pharmacoepidemiol. Drug Saf. 2025;34628-629.

  • Pinilla AH, Clua Espuny JL, Satue Gracia E, Martin Lujan FM, Gentille Lorente D, Palleja Millan M et al. Proactive atrial fibrillation screening in primary care: assessing the impact of a device-based approach. Eur. Heart J. 2025;46.

  • Convertino I, Bissacco CA, Esteban Cledera L, Villalobos F. MPOX Vaccionation in Catalunya: insights on coverage, demographics,and breakthrough cases. Gac. Sanit. 2025;39.

  • Sorup S, Rasmussen TB, Fry C, Villalobos F, Zidan M, van Willigen M et al. Monitoring the Safety of mRNA-1273 COVID-19 Vaccine in the General Population: Results of a Regulator-mandated Post-authorisation Safety Study in Denmark, Norway, Spain, and the United Kingdom (EUPAS44273). Pharmacoepidemiol. Drug Saf. 2025;3493-94.

  • Ehrenstein V, Zidan M, Fry C, Villalobos F, Buranelli C, Lupattelli A et al. Monitoring safety of Moderna COVID-19 vaccines in pregnancy: A multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated postauthorisation safety study in the VAC4EU network (EUPAS44450). Pharmacoepidemiol. Drug Saf. 2025;34611-612.

  • Zurriaga O, Basora J, del Cura I, Maciá MA, Martin E, Pérez AS et al. IMPACT-IC: From initital contacto to follow-up. Gac. Sanit. 2025;39.

  • Riefolo F, Durán CE, Gini R, Messina D, Roberto G, Pazos I et al. Flares of Ten Autoimmune Diseases: Clinical Definitions, Operational Algorithms, and Background Incidence Rates in Seven European Electronic Healthcare Data Sources. Drug Saf. 2025;48(12).

  • Ahmadizar F, Royo AC, Ryan O, Plana E, Arnau JR, Tarazjani AD et al. Evaluating the Safety Profile of the Janssen COVID-19 Vaccine (JCOVDEN): A VAC4EU Post-Authorization Safety Study. Pharmacoepidemiol. Drug Saf. 2025;3494-95.

  • Palà E, Tarazjani AD, Ryan O, Royo AC, Plana E, Bissacco CA et al. Evaluating the Diagnostic Accuracy of Adverse Events of Special Interest Following Janssen COVID-19 Vaccine (JCOVDEN) Using the VAC4EU Validation Pipeline. Pharmacoepidemiol. Drug Saf. 2025;34615-615.

  • Solorzano JM, Villalobos F, Durán C, Riefolo F. Enhancing vaccine safety: developing case definitions to improve detection disease o disease flare-ups. Gac. Sanit. 2025;39.

  • Yeomans A, Aurelius T, Roy D, Morton K, Martínez JJC, Villalobos F et al. Dependence of the Data Source on the Positive Predictive Value in the Retrospective Case Validation of Thrombosis and Thrombocytopenia Syndrome cases using Real-World Data. Pharmacoepidemiol. Drug Saf. 2025;34614-614.

  • Zwiers L, Van der Velden F, St Laurent S, Esposito DB, Zhu L, Urdaneta V et al. Clinical Course and Outcomes of Myocarditis/ Pericarditis Cases following Mrna-1273 Vaccination Compared to Cases not following COVID-19 Vaccination: Interim Analysis of a VAC4EU Cohort Study. Pharmacoepidemiol. Drug Saf. 2025;34629-629.

  • Weibel D, de Luise C, Royo AC, Ryan O, Vaz T, Aguado J et al. 2024 Interim Results from the VAC4EU post-Authorisation Safety Study (PASS) for the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty®) in Europe. Pharmacoepidemiol. Drug Saf. 2025;34615-616.

Anar a l'inici